Azienda USL Toscana Centro
- Address
- lock Available on a paid plan
Neoplasms Research at Azienda USL Toscana Centro
At Azienda USL Toscana Centro in Prato, the clinical trial program is focused on neoplasms, with studies exploring new ways to treat several difficult-to-manage cancers and rare tumors. The research includes work on improving treatment effectiveness, delaying disease progression, and testing promising therapies for both early-stage and advanced disease.
- Endometrial cancer research is evaluating a new maintenance approach for advanced or recurrent disease to better control cancer growth.
- Studies in colorectal cancer are assessing short-course preoperative targeted treatments for molecularly selected resectable tumors.
- Trials in ovarian, fallopian tube, and primary peritoneal cancers are testing maintenance strategies for platinum-sensitive disease.
- Breast cancer research covers both ER-positive/HER2-negative early breast cancer and HER2-low or HER2 IHC 0 metastatic breast cancer, with studies aimed at improving anti-tumor activity and treatment outcomes.
- A rare tumor study is focused on tenosynovial giant cell tumor, evaluating whether a new therapy can reduce tumor activity.
Overall, the site’s oncology team is investigating therapies designed to improve response rates, extend progression-free survival, and support more effective care across a range of solid tumors.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 17 therapeutic areas and 15 of 168 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 160 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 42 by active trials.
- 1Fondazione GONO G.I.6active
lock +41 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Fondazione GONO G.I.10trials
lock +16 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda USL Toscana Centro
lock Showing 1 of 100 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 168 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paclitaxel | 15 | Unknown | 2018-07-31 | 2026-05-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.